IVERIC bio Inc (ISEE)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Glenn P. Sblendorio
Employees:
90
ONE PENN PLAZA, 35TH FLOOR, NEW YORK, NY 10119
212-845-8200

IVERIC bio, Inc. discovers and develops novel treatments for retinal diseases. Zimura, an inhibitor of complement factor C5, is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Data derived from most recent annual or quarterly report
Market Cap 5.504 Billion Shares Outstanding137.783 Million Avg 30-day Volume 5.717 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.77
Price to Revenue0.0 Debt to Equity0.2033 EBITDA-229.636 Million
Price to Book Value6.9916 Operating Margin0.0 Enterprise Value2.832 Billion
Current Ratio15.532 EPS Growth-0.58 Quick Ratio15.237
1 Yr BETA 0.8225 52-week High/Low 39.99 / 9.39 Profit Margin0.0
Operating Cash Flow Growth-65.8807 Free Cash Flow to Firm (FCFF) TTM -146.975 Million Free Cash Flow to Equity (FCFE) TTM-161.207 Million
Altman Z-Score12.4272

Are you looking for this stock instead?

View SEC Filings from ISEE instead.

View recent insider trading info

IVERIC bio Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ISEE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ISEE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-07-13 by BLUMENKRANZ MARK S.
  • 4: filed on 2023-07-13 by CARROLL DAVID FRANCIS
  • 4: filed on 2023-07-13 by MILLER CHRISTINE ANN
  • 4: filed on 2023-07-13 by ROBERTS CALVIN W.
  • 4: filed on 2023-07-13 by SBLENDORIO GLENN
  • 4: filed on 2023-07-13 by SIMMS CHRISTOPHER PAUL
  • 4: filed on 2023-07-13 by DUGEL PRAVIN
  • 4: filed on 2023-07-13 by HENDERSON JANE
  • 4: filed on 2023-07-13 by WESTBY KEITH
  • 4: filed on 2023-07-13 by GIBNEY ANTHONY S

    • Events (8k)

  • 8-K: filed on 2023-07-11:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-06:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-01:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-20:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2023-03-10:
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2022-12-27:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2022-12-12:
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-01:
  • 144: filed on 2023-04-24:
  • 144: filed on 2023-04-21:
  • 144: filed on 2023-06-02:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SBLENDORIO GLENN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-07-11 7

    GRAVES ADRIENNE L

    • Director
    		 0 2023-07-11 3

    HENDERSON JANE

    • Director
    		 0 2023-07-11 3

    ROBERTS CALVIN W.

    • Director
    		 0 2023-07-11 3

    BOLTE AXEL

    • Director
    		 0 2023-07-11 3

    BLUMENKRANZ MARK S.

    • Director
    		 0 2023-07-11 3

    WESTBY KEITH SVP, CHIEF OPERATING OFFICER

    • Officer
    		 0 2023-07-11 14

    DUGEL PRAVIN PRESIDENT

    • Officer
    • Director
    		 0 2023-07-11 6

    CARROLL DAVID FRANCIS SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-07-11 8

    GIBNEY ANTHONY S EVP, CHIEF BUSINESS OFFICER

    • Officer
    		 0 2023-07-11 4

    SIMMS CHRISTOPHER PAUL SVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2023-07-11 3

    MILLER CHRISTINE ANN

    • Director
    		 0 2023-07-11 4

    GUYER DAVID R EXECUTIVE CHAIRMAN

    • Officer
    • Director
    		 0 2020-12-18 0

    VERSANT VENTURE CAPITAL IV, L.P.

    VERSANT SIDE FUND IV, L.P.

    VERSANT VENTURES IV, LLC

    • 10% Owner
    		 No longer subject to file 2020-06-19 0

    REDLICK DAVID E

    • Director
    		 0 2019-05-15 0

    ROSS MICHAEL JAY

    • Director
    		 0 2018-05-23 0

    WOOD BARBARA A SVP, GEN. COUNSEL, SECRETARY

    • Officer
    		 16,462 2018-01-04 0

    PATEL SAMIR CHANDRAKANT PRESIDENT

    • Officer
    • Director
    		 15,813 2017-01-04 0

    BJARKE HENRIC BJORN SVP & CCO

    • Officer
    		 1,684 2017-01-04 0

    NOVO A/S

    • 10% Owner
    		 No longer subject to file 2016-12-14 0

    SMITH IAN F

    • Director
    		 0 2016-08-02 0

    GALAKATOS NICHOLAS

    • Director
    		 9,629 2016-01-11 0

    ATIEH MICHAEL G EVP, CFO, & CBO, TREASURER

    • Officer
    		 295 2016-01-02 0

    CLARUS LIFESCIENCES II, L.P.

    CLARUS VENTURES II GP, L.P.

    CLARUS VENTURES II, LLC

    GALAKATOS NICHOLAS

    HENNER DENNIS

    LIPTAK ROBERT

    SIMON NICHOLAS

    STEINMETZ MICHAEL

    WHEELER KURT

    • Director
    • 10% Owner
    		 No longer subject to file 2015-05-26 0

    SMITH TODD N SVP & CCO

    • Officer
    		 0 2015-01-02 0

    PEACOCK BRUCE CFO & CBO

    • Officer
    		 0 2014-09-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    IVERIC BIO INC ISEE 2023-07-12 22:15:04 UTC 4.6518 0.4082 2400000
    IVERIC BIO INC ISEE 2023-07-12 21:45:03 UTC 4.6518 0.4082 2400000
    IVERIC BIO INC ISEE 2023-07-12 21:15:04 UTC 4.6518 0.4082 2400000
    IVERIC BIO INC ISEE 2023-07-12 20:45:05 UTC 4.6518 0.4082 2400000
    IVERIC BIO INC ISEE 2023-07-12 20:15:06 UTC 4.6518 0.4082 2500000
    IVERIC BIO INC ISEE 2023-07-12 19:45:03 UTC 4.6518 0.4082 2500000
    IVERIC BIO INC ISEE 2023-07-12 19:15:04 UTC 4.6518 0.4082 2400000
    IVERIC BIO INC ISEE 2023-07-12 18:45:04 UTC 4.641 0.419 2400000
    IVERIC BIO INC ISEE 2023-07-12 18:15:03 UTC 4.641 0.419 2500000
    IVERIC BIO INC ISEE 2023-07-12 17:45:03 UTC 4.641 0.419 2600000
    IVERIC BIO INC ISEE 2023-07-12 17:15:04 UTC 4.641 0.419 2600000
    IVERIC BIO INC ISEE 2023-07-12 16:45:04 UTC 4.6402 0.4298 2600000
    IVERIC BIO INC ISEE 2023-07-12 16:15:03 UTC 4.6402 0.4298 2600000
    IVERIC BIO INC ISEE 2023-07-12 15:45:04 UTC 4.6402 0.4298 2300000
    IVERIC BIO INC ISEE 2023-07-12 15:15:04 UTC 4.6402 0.4298 2200000
    IVERIC BIO INC ISEE 2023-07-12 14:45:04 UTC 4.6402 0.4298 2200000
    IVERIC BIO INC ISEE 2023-07-12 14:15:04 UTC 4.6402 0.4298 2200000
    IVERIC BIO INC ISEE 2023-07-12 13:45:04 UTC 4.82 0.25 2200000
    IVERIC BIO INC ISEE 2023-07-12 13:15:04 UTC 4.82 0.25 2200000
    IVERIC BIO INC ISEE 2023-07-12 12:45:04 UTC 4.82 0.25 2200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund ISEE -3500.0 shares, $-56840.0 2021-09-30 N-PORT
    Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio ISEE -47700.0 shares, $-774648.0 2021-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments